June 15 (Reuters) - Roche Holding AG ROG.S:
[AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR] ROCHE PROVIDES SAFETY UPDATE ON ELEVIDYS™ GENE THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY IN NON-AMBULATORY PATIENTS
ROCHE HOLDING AG - PAUSES DOSING OF ELEVIDYS IN NON-AMBULATORY PATIENTS
ROCHE HOLDING AG - WORKING WITH HEALTH AUTHORITIES TO MODIFY PATIENT CARE
ROCHE HOLDING AG - DECISION FOLLOWS TWO CASES OF FATAL ACUTE LIVER FAILURE IN NON-AMBULATORY PATIENTS
ROCHE HOLDING AG - NEW DOSING RESTRICTIONS DO NOT IMPACT AMBULATORY DMD PATIENTS
ROCHE HOLDING AG - EUROPEAN REGULATORS REQUEST TEMPORARY CLINICAL HOLDS ON ELEVIDYS STUDIES
Source text: ID:nGNEc634Nc
Further company coverage: ROG.S
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.